A novel canine histiocytic sarcoma cell line:initial characterization and utilization for drug screening studies

In order to be responsible stewards of other people’s data, cloud providers must be accountable for their data handling practices. The potential long provider chains in cloud computing introduces additional accountability challenges, and this paper examines requirements which must be fulfilled to achieve an accountability-based approach.acceptedVersio

A novel canine histiocytic sarcoma cell line:initial characterization and utilization for drug screening studies

Abstract Background Histiocytic sarcoma is a rare disorder in humans, however it is seen with appreciable frequency in certain breeds of dogs, such as Bernese mountain dog. The purpose of this study was to fully characterize a novel canine histiocytic sarcoma cell line, and utilize it as a tool to screen for potential therapeutic drugs. Methods The histiocytic sarcoma cell line was characterized by expression of cellular markers as determined by immunohistochemistry and flow cytometry techniques. The neoplastic cells were also evaluated for their capability of phagocytizing beads particles, and their potential to grow as xenograft in an immunodeficient mouse. We investigated the in vitro cytotoxic activity of a panel of thirteen compounds using the MTS proliferation assay. Inhibitory effects of different drugs were compared using one-way ANOVA, and multiple means were compared using Tukey’s test. Results Neoplastic cells expressed CD11c, CD14, CD18, CD45, CD172a, CD204, MHC I, and vimentin. Expression of MHC II was upregulated after exposure to LPS. Furthermore, the established cell line clearly demonstrated phagocytic activity similar to positive controls of macrophage cell line. The xenograft mouse developed a palpable subcutaneous soft tissue mass after 29 days of inoculation, which histologically resembled the primary neoplasm. Dasatinib, a tyrosine kinase pan-inhibitor, significantly inhibited the growth of the cells in vitro within a clinically achievable and tolerable plasma concentration. The inhibitory response to dasatinib was augmented when combined with doxorubicin. Conclusions In the present study we demonstrated that a novel canine histiocytic sarcoma cell line presents a valuable tool to evaluate novel treatment approaches. The neoplastic cell line favorably responded to dasatinib, which represents a promising anticancer strategy for the treatment of this malignancy in dogs and similar disorders in humans

Energy efficiency maximization in the uplink Delta-OMA networks

Abstract Delta-orthogonal multiple access (D-OMA) has been recently investigated as a potential technique to enhance the spectral efficiency in the sixth-generation (6G) networks. D-OMA enables partial overlapping of the adjacent sub-channels that are assigned to different clusters of users served by non-orthogonal multiple access (NOMA), at the expense of additional interference. In this paper, we analyze the performance of D-OMA in the uplink and develop a multi-objective optimization framework to maximize the uplink energy efficiency (EE) in a multi-access point (AP) network enabled by D-OMA. Specifically, we optimize the sub-channel and transmit power allocations of the users as well as the overlapping percentage of the spectrum between the adjacent sub-channels. The formulated problem is a mixed binary non-linear programming problem. Therefore, to address the challenge we first transform the problem into a single-objective problem using Tchebycheff method. Then, we apply the monotonic optimization (MO) to explore the hidden monotonicity of the objective function and constraints, and reformulate the problem into a standard MO in canonical form. The reformulated problem can be solved by applying the outer polyblock approximation method. Our numerical results show that D-OMA outperforms the conventional non-orthogonal multiple access (NOMA) and orthogonal frequency division multiple access (OFDMA) when the adjacent sub-channel overlap and scheduling are optimized jointly